Real-time RT-PCR: A complementary method to detect HER-2 status in breast carcinoma

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4679-4683

  Bossard, Céline ^a,c,d   Bieche, Ivan ^a,b   Le Doussal, Viviane ^a   Lidereau, Rosette ^a   Sabourin, Jean Christophe ^a  

^a CENTRE RENÉ HUGUENIN   (France)

^b FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^c HÔTEL DIEU   (France)

^d INSERM   (France)

Author keywords

HER 2 status; Invasive breast carcinoma; Real time quantitative RT PCR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

EID: 28444432969     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Quirke P, Pickles A, Tuzi NL, Mohamdee O and Gullick WJ: Pattern of expression of c-erbB-2 oncoprotein in human fetuses. Br J Cancer 60: 64-69, 1989.
2. Di Augustine R and Richards RG: EGF-related peptides and their receptors in mammary gland development. J Mam Gland Bio Neoplasia 2: 109-118, 1997.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 255: 177-182, 1987.
4. Hamilton A and Piccart M: The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. J Oncol 11: 647-663, 2000.
5. Révillon F, Bonneterre J and Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34: 791-808, 1998.
6. Piccart M, Lohrisch C, Di Leo A and Larsimont D: The predictive value of HER2 in breast cancer. Oncology 61: 73-82, 2001.
7. Colomer R, Lupu R, Bacus SS and Gelman EP: erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 70: 819-825, 1994.
8. Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Woher J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER2. N Engl J Med 344: 783-792, 2001.
9. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris NL, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ and Press M: Efficacy and safety of trastuzumab as a single agent in first line treatment of HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002.
10. Baselga J, Gianni L, Geyer C, Perez EA, Riva A and Jackisch C: Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol 31: 51-57, 2004.
11. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG and Somerfield MR: 2000 update of recommendations for the use of tumor markers in band colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865-1878, 2001.
12. Pauletti G, Godolphin W, Press MF and Slamon DJ: Detection and quantification of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13: 63-72, 1996.
13. Press MF, Bernstein L, Thomas PA Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Philips RN, Ross JS, Wolman SR and Flom JK: HER-2/neu gene amplification characterized by fluorescent in situ hybridization: poor prognosis in lymph node -negative breast carcinomas. J Clin Oncol 15: 2894-2904, 1997.
14. Vogel CL and Franco SX: Clinical experience with trastuzumab (Herceptin). Breast J 9: 452, 2003.
15. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Simmans W, Lajos Pusztai and Hortobagyi G: Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics Feb 3, 2004 [Epub ahead of print].
16. Bilous M, F.R.C.P.A., Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Rüschoff J, Tomasic G and Van De Vijver M: Current perspectives on HER-2 testing: a review of national testing guidelines. Mod Pathol 16: 173-182, 2003.
17. Dandachi N, Dietze O and Hauser-Kronberger C: Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER-2 oncogene in archival human breast carcinoma. Lab Invest 82: 1007-1014, 2002.
18. Kumamoto H, Sasano H, Taniguchi T, Suzuki T, Moriya T and Ichinohasama R: Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int 51: 579-584, 2001.
19. Tanner M, Gancberg D, Di leo A, Larsimont D, Rouas G, Piccart MJ and Isola J: Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 157: 1467-1472, 2000.
20. Bièche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R and Vidaud M: Real-time RT-PCR reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 45: 1148-1156, 1999.
21. Farabegoli F, Ceccarelli C, Santini D, Baldini N, Taffurelli M, Marrano D, Trere D and Derenzini M: c-erbB-2 overexpression in amplified and non-amplified breast carcinoma samples. Int J Cancer 84: 273-277, 1999.
22. Guerin M, Barrois M, Terrier MJ, Spielmann M and Riou G: Overexpression of either c-myc or c-erbB-2/neu proto-oncogene in human breast carcinomas: correlation with poor prognosis. Oncogene Res 3: 21-31, 1988.
23. King CR, Swain SM, Porter L, Steinberg SM, Lippman ME and Gelman EP: Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. Cancer Res 49: 4185-4191, 1989.
24. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R and Slamon DJ: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18: 3651-3664, 2000.
25. Robertson KW, Reeves JR, Smith G, Keith WN, Ozanne BW, Cooke TG and Stanton PD: Quantitative estimation of epidermal growth factor and c-erbB-2 in human breast cancer. Cancer Res 56: 3823-3830, 1996.
26. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
27. Revillon F, Hornez L and Peyrat JP: Quantification of c-erb-B2 gene expression in breast cancer by competitive RT-PCR. Clin Chem 43: 2114-2120, 1997.
28. Mrhalova M, Kodet R, Kalinova M and Hilska I: Relative quantification of ERBB-2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 gene copy number. Pathol Res Prac 199: 453-461, 2003.
29. Lehmann U, Glockner S, Kleeberger W, von Wasielewski HF and Kreipe H: Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol 156: 1855-1864, 2000.
30. Bankfalvi A, Simon R, Brandt B, Bürger H, Vollmer I, Dockhorn-Dworniczak B, Lelle RJ and Boecker W: Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology 37: 411-419, 2000.
31. De Cremoux P, Martin EC, Vincent-Salomon A, Dieras V, Barbaroux C, Liva S, Pouillart P, Sastre-Garau X and Magdalenat H: Quantitative PCR analysis of c-erb-B2 gene amplification and comparison with p185 protein expression in breast cancer drill biopsies. Int J Cancer 83: 157-161, 1999.
32. Lehr HA, Jacobs TW, Yaziji H, Schnitt SJ and Gown AM: Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. Am J Clin Pathol 115: 814-822, 2001.
33. O'Malley FP, Parkes R, Latta E, Tjan S, Zadro T, Mueller R, Arnesson N, Blackstein M and Andrulis I: Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol 116: 806-810, 2001.